

VEGF R2/KDR

Catalog # PVGS1815

Specification

VEGF R2/KDR - Product Information

Primary Accession **Species** Human P35968-1

Sequence

Ala20-Glu764

Purity

> 95% as determined by Bis-Tris PAGE
> > 95% as determined by HPLC

Endotoxin Level

Less than 1EU per µg by the LAL method.

Biological Activity

Immobilized Human VEGF165 at 1 μ g/ml (100 μ l/well) on the plate can bind VEGF R2/KDR mFc Chimera, Human (Cat.No.: Z03966)

Expression System

HEK293

Theoretical Molecular Weight

110 kDa

Formulation Lyophilized from a 0.22 µm filtered solution in PBS, (pH 7.4).

Reconstitution

It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH₂0 more than 100 μ g/ml.

Storage & Stability


Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

VEGF R2/KDR - Additional Information

Target Background

Vascular endothelial growth factor receptor 2 (VEGFR2) is one kind of tyrosine kinase receptors. VEGFR2 acts as a cell-surface receptor for VEGFA, VEGFB and PGF. It plays an important role in the development of embryonic vasculature, cell survival and cancer cell invasion. VEGFR2 is a key regulator of angiogenesis.

VEGF R2/KDR - Protein Information





VEGF R2/KDR - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Western Blot
- Blocking Peptides
- Dot Blot
- <u>Immunohistochemistry</u>
- <u>Immunofluorescence</u>
- <u>Immunoprecipitation</u>
- Flow Cytomety
- Cell Culture

VEGF R2/KDR - Images